Daniel Metzger
Overview
Explore the profile of Daniel Metzger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
11202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giannini M, Rovito D, Oulad-Abdelghani M, Messaddeq N, Debrut L, Quiring G, et al.
RMD Open
. 2025 Mar;
11(1).
PMID: 40044571
Introduction: Inflammatory myopathies (IM) are a group of severe autoimmune diseases, sharing some similarities, whose cause is unknown and treatment is empirical.While C-protein-induced myositis (CIM), the most currently used mouse...
2.
Len-Tayon K, Metzger D, Laverny G
Med Sci (Paris)
. 2025 Mar;
41(2):154-159.
PMID: 40028953
Prostate cancer is the third leading cause of cancer-related death among men in developed countries. Hormone and chemotherapy are the standard of care for advanced prostate cancer, but most patients...
3.
Metzger D, Greenspun B, Siolas D, Jafari M
Ann Surg Oncol
. 2025 Feb;
PMID: 40009308
No abstract available.
4.
Amirault K, Collins M, Beker L, Mills B, Werner M, Andreas J, et al.
SLAS Technol
. 2025 Feb;
31:100252.
PMID: 39892788
Comprehensive Genomic Profiling (CGP) has emerged as a progressive standard of care for the understanding clinical oncology and treatment of solid tumors (Conroy, Pabla et al. 2021). By identifying actionable...
5.
Yanushko D, German Falcon B, El Bizri R, Pervizou D, Dolgos R, Keime C, et al.
Cell Death Dis
. 2025 Jan;
16(1):46.
PMID: 39865080
Prostate cancer is a heterogeneous disease with a slow progression and a highly variable clinical outcome. The tumor suppressor genes PTEN and TP53 are frequently mutated in prostate cancer and...
6.
Len-Tayon K, Beraud C, Fauveau C, Belorusova A, Chebaro Y, Mourino A, et al.
Br J Pharmacol
. 2024 Jul;
181(21):4279-4293.
PMID: 38982588
Background And Purpose: Castration-resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first-line treatment, docetaxel. The benefits of vitamin...
7.
Cai Q, Sahu R, Ueberschlag-Pitiot V, Souali-Crespo S, Charvet C, Silem I, et al.
Nat Commun
. 2024 Apr;
15(1):3563.
PMID: 38670969
Synthetic glucocorticoids (GC), such as dexamethasone, are extensively used to treat chronic inflammation and autoimmune disorders. However, long-term treatments are limited by various side effects, including muscle atrophy. GC activities...
8.
Terzic J, Metzger D
Med Sci (Paris)
. 2023 Nov;
39(10):709-711.
PMID: 37943128
No abstract available.
9.
Schreihofer D, Dalwadi D, Kim S, Metzger D, Oppong-Gyebi A, Das-Earl P, et al.
Transl Stroke Res
. 2023 Sep;
15(6):1035-1049.
PMID: 37704905
Sigma 1 receptors are intracellular chaperone proteins that have been explored as a subacute treatment to enhance post-stroke recovery. We recently identified the antitussive oxeladin as a selective sigma 1...
10.
Ghaibour K, Rizk J, Ebel C, Ye T, Philipps M, Schreiber V, et al.
J Vis Exp
. 2023 Jul;
(197).
PMID: 37486110
Genome-wide analyses with small cell populations are a major constraint for studies, particularly in the stem cell field. This work describes an efficient protocol for the fluorescence-activated cell sorting (FACS)...